Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting
RBC Flags Seasonal Pressures Impacting Karyopharm Therapeutics Inc. (KPTI) Short-Term Performance [Yahoo! Finance]
Karyopharm Therapeutics (KPTI) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $8.00 price target on the stock, down from $12.00.
Karyopharm: Putting The Phase 3 Trial In Context [Seeking Alpha]
Karyopharm Therapeutics (KPTI) had its price target lowered by Robert W. Baird from $21.00 to $15.00. They now have an "outperform" rating on the stock.